ArticleInternational journal of clinical and experimental pathology2026
CYP2D6 gene polymorphisms influence postoperative pain sensitivity and drug response in lung cancer surgery.
Article in International journal of clinical and experimental pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Impact of UGT1A9 Expression on Analgesic Efficacy and Safety of Postoperative Ketorolac in Thyroid Cancer Surgery: A Prospective Cohort Study.Journal of pain research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the role of CYP2D6 gene polymorphism expression in postoperative pain sensitivity and individualized drug response in lung cancer patients undergoing thoracoscopic surgery.
methodsSixty patients (aged 40-80 years, ASA I-III) undergoing thoracoscopic lung surgery between January 2024 and March 2025 were enrolled. Preoperative blood samples were collected to assess CYP2D6 gene expression. Based on enzyme activity, patients were divided into two groups: Group I (high CYP2D6 expression, n=30) and Group II (low expression, n=30). All patients received standardized anesthesia and postoperative analgesia with tramadol. Evaluated outcomes included: CYP2D6 gene activity; pain scores at 2, 4, 6, 8, and 10 hours postoperatively (VAS); PCA pump usage; ST-T segment changes on ECG; incidence of adverse events (sweating, nausea, vomiting, urinary retention); time to first cough and ambulation; and length of hospital stay.
resultsGroup I showed significantly higher CYP2D6 expression (P<0.01). Postoperative VAS scores and PCA usage (T2-T5) were significantly greater in Group I (P<0.01). ST-T changes were more pronounced in Group I at T2 and T5 (P<0.01). Group II had a higher incidence of adverse reactions (P<0.05) but demonstrated earlier coughing, earlier ambulation, and shorter hospital stays (P<0.01). No significant differences in age, weight, height, BMI, or surgical time were observed.
conclusionPatients with low CYP2D6 activity experienced stronger and longer analgesic effects after surgery. CYP2D6 genotyping may support personalized pain management in lung cancer surgery, promoting enhanced recovery (ERAS) and reduced hospital burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.